No Heart Risk From Stop-Smoking Drugs Chantix and Zyban: Study
Title: No Heart Risk From Stop-Smoking Drugs Chantix and Zyban: StudyCategory: Health NewsCreated: 4/10/2018 12:00:00 AMLast Editorial Review: 4/11/2018 12:00:00 AM (Source: MedicineNet Heart General)
Source: MedicineNet Heart General - April 11, 2018 Category: Cardiology Source Type: news

Study: Stop-smoking drugs Chantix, Zyban pose no heart risks
New research shows the stop-smoking drugs Chantix and Zyban are as safe for the heart as nicotine patches and dummy pills. (Source: ABC News: Health)
Source: ABC News: Health - April 9, 2018 Category: Consumer Health News Tags: Health Source Type: news

Study: Chantix reduces smoking one year after heart attack
The drug varenicline, marketed as Chantix, reduced smoking among patients who had suffered a heart attack one year earlier, according to a controlled trial. (Source: Health News - UPI.com)
Source: Health News - UPI.com - March 26, 2018 Category: Consumer Health News Source Type: news

Smoking in patients with heart attack reduced with varenicline
(Canadian Medical Association Journal) In patients who have had a heart attack, the drug varenicline significantly reduced smoking during the following year, found a randomized controlled trial published in CMAJ (Canadian Medical Association Journal). (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - March 26, 2018 Category: International Medicine & Public Health Source Type: news

Pfizer's quit-smoking Chantix fails study in adolescent smokers
(Reuters) - Pfizer Inc said on Friday its study to test safety and effectiveness of its anti-smoking treatment Chantix in adolescent smokers failed to meet the main goal. (Source: Reuters: Health)
Source: Reuters: Health - March 23, 2018 Category: Consumer Health News Tags: healthNews Source Type: news

La FDA revisa la descripci ón de los efectos secundarios para la salud mental de los medicamentos para dejar de fumar Chantix (vareniclina) y Zyban (bupropión) para reflejar las conclusiones de estudio clínico
FDA revises description of mental health side effects of the stop-smoking medicines Chantix (varenicline) and Zyban (bupropion) to reflect clinical trial findings (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - March 8, 2018 Category: Drugs & Pharmacology Source Type: news

La FDA revisa la descripci ó n de los efectos secundarios para la salud mental de los medicamentos para dejar de fumar Chantix (vareniclina) y Zyban (bupropi ó n) para reflejar las conclusiones de estudio cl í nico
FDA revises description of mental health side effects of the stop-smoking medicines Chantix (varenicline) and Zyban (bupropion) to reflect clinical trial findings (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - March 8, 2018 Category: Drugs & Pharmacology Source Type: news

FDA Drug Safety Communication: FDA revises description of mental health side effects of the stop-smoking medicines Chantix (varenicline) and Zyban (bupropion) to reflect clinical trial findings
An FDA review found the side effects on mood, behavior, or thinking with the stop-smoking medicines Chantix (varenicline) and Zyban (bupropion) are lower than previously suspected. These risks still exist, but we believe the benefits of quitting smoking outweigh them. (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - March 8, 2018 Category: Drugs & Pharmacology Source Type: news

Comunicado de la FDA sobre la seguridad de los medicamentos: La FDA actualiza la etiqueta del medicamento para dejar de fumar Chantix (vareniclina), para incluir la posible interacci ón con el alcohol, un riesgo poco común de sufrir convulsiones, y los estudios de efectos secundarios en el estado de ánimo, la conducta o el pensamiento
[3-9-2015] La Administraci ón de Alimentos y Medicamentos de los Estados Unidos (FDA, por sus siglas en inglés) advierte que el medicamento de prescripción médica para dejar de fumar Chantix (vareniclina) puede alterar el modo en que las personas reaccionan al alcohol. (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - February 26, 2018 Category: Drugs & Pharmacology Source Type: news

NIAAA Spectrum: Anti-Smoking Medication May Reduce Alcohol Craving
Varenicline, an anti-smoking medication, may reduce craving for alcohol in people who drink heavily and for people with alcohol use disorder (AUD) who are also depressed, according to two recent studies. The research, funded by NIAAA and led by Sherry McKee, Ph.D., Professor of Psychiatry at Yale School of Medicine, provides more evidence that varenicline may be a potential treatment for AUD. (Source: NIAAA News)
Source: NIAAA News - February 15, 2018 Category: Addiction Authors: Kimberly Source Type: news

FDA Drug Safety Communication: Safety review update of Chantix (varenicline) and risk of neuropsychiatric adverse events
[10-24-2011] The U.S. Food and Drug Administration (FDA) has reviewed the results from two FDA-sponsored epidemiological studies that evaluated the risk of neuropsychiatric adverse events associated with the smoking cessation drug Chantix (varenicline). (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - February 9, 2018 Category: Drugs & Pharmacology Source Type: news

Varenicline Decreases Heavy Drinking in Male Smokers Varenicline Decreases Heavy Drinking in Male Smokers
Varenicline is FDA-approved as an agent to assist with smoking cessation. A new study suggests it may be useful in reducing heavy drinking in male smokers with comorbid alcohol use disorder.Medscape Medical News (Source: Medscape Psychiatry Headlines)
Source: Medscape Psychiatry Headlines - January 11, 2018 Category: Psychiatry Tags: Psychiatry News Source Type: news

Dead is dead: Drug for helping smokers quit found to increase risk of heart attack AND self-harm
(Natural News) Pfizer’s flagship smoking cessation drug varenicline, sold under the brand names Chantix in the United States and Champix in Canada and Europe, may do more harm than good as recent research published in the American Journal of Respiratory and Critical Care Medicine showed that the medication was associated with an increased likelihood of suffering from cardiovascular conditions. A... (Source: NaturalNews.com)
Source: NaturalNews.com - January 3, 2018 Category: Consumer Health News Source Type: news

Varenicline for Smoking Cessation Linked to Cardiac Events Varenicline for Smoking Cessation Linked to Cardiac Events
Observational results show increased risk for cardiovascular events in patients prescribed varenicline to stop smoking, although researchers say the benefit of smoking cessation may be worth the risk.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - January 2, 2018 Category: Consumer Health News Tags: Cardiology News Source Type: news

Varenicline May Increase Cardiovascular Risk
(MedPage Today) -- Observational study found 34% higher rates of CV events after starting stop-smoking drug (Source: MedPage Today Primary Care)
Source: MedPage Today Primary Care - December 21, 2017 Category: Primary Care Source Type: news

Stop-smoking drug increases users' risk of a heart attack
Researchers from the University of Toronto found varenicline, which is prescribed under the brand name Chantix, raises users' chances of being hospitalized due to a cardiovascular event. (Source: the Mail online | Health)
Source: the Mail online | Health - December 20, 2017 Category: Consumer Health News Source Type: news

Varenicline Use Tied to Elevated Risk for Cardiovascular Hospitalizations
The smoking cessation drug varenicline is associated with increased risk for cardiovascular hospitalizations, according to a self-controlled study in the American Journal of Respiratory... (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - December 20, 2017 Category: Primary Care Source Type: news

Smoking cessation drug may increase risk of adverse cardiovascular event
(American Thoracic Society) Varenicline, one of the most commonly prescribed drugs for helping people quit smoking, may put them at higher risk for a cardiovascular event, according to new research published online in the American Journal of Respiratory and Critical Care Medicine. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - December 20, 2017 Category: International Medicine & Public Health Source Type: news

FDA Drug Safety Communication: FDA updates label for stop smoking drug Chantix (varenicline) to include potential alcohol interaction, rare risk of seizures, and studies of side effects on mood, behavior, or thinking
[03-09-2015] The U.S. Food and Drug Administration (FDA) is warning that the prescription smoking cessation medicine Chantix (varenicline) can change the way people react to alcohol. (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - December 11, 2017 Category: Drugs & Pharmacology Source Type: news

Smoking study personalizes treatment
(Vanderbilt University Medical Center) A simple blood test is allowing Vanderbilt University Medical Center (VUMC) researchers to determine which patients should be prescribed varenicline (Chantix) to stop smoking and which patients could do just as well, and avoid side effects, by using a nicotine patch. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - November 20, 2017 Category: International Medicine & Public Health Source Type: news

Identification and characteristics of time-related shifts in suicide-related event frequency during smoking cessation treatment with varenicline - Akimoto H, Wakiyama H, Oshima S, Negishi A, Ohara K, Numajiri S, Okita M, Ohshima S, Inoue N, Kobayashi D.
OBJECTIVES: To survey time-related shifts in number of suicide-related events (SRE) during smoking cessation treatment with varenicline (VAR) in cases from the U.S. Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS), as well as the c... (Source: SafetyLit)
Source: SafetyLit - September 22, 2017 Category: International Medicine & Public Health Tags: Alcohol and Other Drugs Source Type: news

A Single Drug Could One Day Treat Pain, Memory Loss And Nicotine Addiction
Pain, memory problems and nicotine addiction are formidable problems that have quite different consequences. But in terms of what’s happening in the brain that causes people to suffer from each, they share a close connection. And now scientists say one drug might be able to help people with all three of these problems. Estimates suggest 2 million people in the U.S. suffered from an opioid abuse disorder in 2015 (the most recent year with data available), about 5 million Americans are currently living with Alzheimer’s disease and more than 36 million Americans are currently cigarette smokers (more than half of w...
Source: Healthy Living - The Huffington Post - May 31, 2017 Category: Consumer Health News Source Type: news

A Single Drug Could One Day Treat Pain, Memory Loss And Nicotine Addiction
Pain, memory problems and nicotine addiction are formidable problems that have quite different consequences. But in terms of what’s happening in the brain that causes people to suffer from each, they share a close connection. And now scientists say one drug might be able to help people with all three of these problems. Estimates suggest 2 million people in the U.S. suffered from an opioid abuse disorder in 2015 (the most recent year with data available), about 5 million Americans are currently living with Alzheimer’s disease and more than 36 million Americans are currently cigarette smokers (more than half of w...
Source: Science - The Huffington Post - May 31, 2017 Category: Science Source Type: news

Researchers warn of hazards of smoking and need for wider use of varenicline to quit
More than 35 million Americans are trying to quit smoking. Researchers reassure clinicians and their patients that varenicline, whose brand name is Chantix, is a safe and effective way to achieve smoking cessation and that failure to use this drug has caused preventable heart attacks and deaths from cardiovascular disease. Just a few months ago, the FDA removed the black box warning from varenicline. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - March 27, 2017 Category: Science Source Type: news

Researchers warn of hazards of smoking and need for wider use of varenicline to quit
(Florida Atlantic University) More than 35 million Americans are trying to quit smoking. Researchers reassure clinicians and their patients that varenicline, whose brand name is Chantix, is a safe and effective way to achieve smoking cessation and that failure to use this drug has caused preventable heart attacks and deaths from cardiovascular disease. Just a few months ago, the FDA removed the black box warning from varenicline. (Source: EurekAlert! - Social and Behavioral Science)
Source: EurekAlert! - Social and Behavioral Science - March 27, 2017 Category: Global & Universal Source Type: news

Smoking Cessation Drug May Boost Cognition in Schizophrenia Smoking Cessation Drug May Boost Cognition in Schizophrenia
The smoking cessation drug varenicline may help treat cognitive deficits in schizophrenia patients who smoke and allay worsening cognition when they try to quit.Medscape Medical News (Source: Medscape Psychiatry Headlines)
Source: Medscape Psychiatry Headlines - March 16, 2017 Category: Psychiatry Tags: Psychiatry News Source Type: news

Smoking-Cessation Meds, Counseling Work in Patients With CVD Smoking-Cessation Meds, Counseling Work in Patients With CVD
In contrast with some earlier research, a meta-analysis found that varenicline and bupropion along with counseling by phone or in person all seem effective in patients with cardiovascular disease.Heartwire from Medscape (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - January 24, 2017 Category: Consumer Health News Tags: Cardiology News Source Type: news

A combination of naltrexone + varenicline retards the expression of a genetic predisposition toward high alcohol drinking - Froehlich JC, Fischer SM, Nicholson ER, Dilley JE, Filosa NJ, Smith TN, Rademacher LC.
This study examined whether naltrexone (NTX) or varenicline (VAR), alone or in combination, can retard the phenotypic expression of a genetic predisposition toward high alcohol drinking in rats selectively bred for high alcohol intake when drug... (Source: SafetyLit)
Source: SafetyLit - January 14, 2017 Category: Global & Universal Tags: Alcohol and Other Drugs Source Type: news

La FDA revisa la descripci ó n de los efectos secundarios para la salud mental de los medicamentos para dejar de fumar Chantix (vareniclina) y Zyban (bupropi ó n) para reflejar las conclusiones de estudio cl í nico
FDA revises description of mental health side effects of the stop-smoking medicines Chantix (varenicline) and Zyban (bupropion) to reflect clinical trial findings (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - January 5, 2017 Category: Drugs & Pharmacology Source Type: news

La FDA revisa la descripci ón de los efectos secundarios para la salud mental de los medicamentos para dejar de fumar Chantix (vareniclina) y Zyban (bupropión) para reflejar las conclusiones de estudio clínico
FDA revises description of mental health side effects of the stop-smoking medicines Chantix (varenicline) and Zyban (bupropion) to reflect clinical trial findings (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - January 5, 2017 Category: Drugs & Pharmacology Source Type: news

FDA Smokes Black Box Warning on Chantix FDA Smokes Black Box Warning on Chantix
Siding with an advisory committee, the FDA approved dropping the black box warning regarding possible serious neuropsychiatric side effects with Pfizer's smoking cessation drug varenicline.Medscape Medical News (Source: Medscape Psychiatry Headlines)
Source: Medscape Psychiatry Headlines - December 19, 2016 Category: Psychiatry Tags: Psychiatry News Source Type: news

Black Box Warnings Removed From Chantix, Zyban
(Source: WebMD Health)
Source: WebMD Health - December 19, 2016 Category: Consumer Health News Source Type: news

Health Highlights: Dec. 19, 2016
Here are some of the latest health and medical news developments, compiled by the editors of HealthDay: Black Box Warnings Removed From Chantix and Zyban The anti-smoking drug Chantix no longer has to carry a bold-letter warning about possible... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - December 19, 2016 Category: Journals (General) Source Type: news

FDA Removes Black Box Warning from Varenicline's Label (FREE)
By Kristin J. Kelley Edited by Susan Sadoughi, MD, and Andr é Sofair, MD, MPH The FDA has agreed to remove the black box warning from the label of the smoking-cessation drug, varenicline (Chantix). The warning alerted patients about the … (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - December 18, 2016 Category: Primary Care Source Type: news

FDA Drug Safety Communication: FDA revises description of mental health side effects of the stop-smoking medicines Chantix (varenicline) and Zyban (bupropion) to reflect clinical trial findings
An FDA review found the side effects on mood, behavior, or thinking with the stop-smoking medicines Chantix (varenicline) and Zyban (bupropion) are lower than previously suspected. These risks still exist, but we believe the benefits of quitting smoking outweigh them. (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - December 16, 2016 Category: Drugs & Pharmacology Source Type: news

Pfizer get OK to remove 'black box' warning on smoking cessation drug
The Food and Drug Administration has agreed to Pfizer ’s request to remove a boxed warning on its medicine prescribed to help people quit smoking. The company’s Chantix product previous carried a "black box" warning of potential neuropsychiatric events associated with the drug. Pfizer (NYSE: PFE) said the removal of the boxed warning was based on positive outcomes from what it described as the largest smoking cessation clinical trial, which involved 8,000 patients with and without histories… (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - December 16, 2016 Category: American Health Authors: John George Source Type: news

Pfizer get OK to remove 'black box' warning on smoking cessation drug
The Food and Drug Administration has agreed to Pfizer ’s request to remove a boxed warning on its medicine prescribed to help people quit smoking. The company’s Chantix product previous carried a "black box" warning of potential neuropsychiatric events associated with the drug. Pfizer (NYSE: PFE) said the removal of the boxed warning was based on positive outcomes from what it described as the largest smoking cessation clinical trial, which involved 8,000 patients with and without histories… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - December 16, 2016 Category: Biotechnology Authors: John George Source Type: news

Chantix Loses Boxed Warning on Psych Effects
(MedPage Today) -- Label will still note serious neuropsychiatric risk but without the black box (Source: MedPage Today Psychiatry)
Source: MedPage Today Psychiatry - December 16, 2016 Category: Psychiatry Source Type: news

Chantix, Zyban Lose Boxed Warning on Psych Effects
(MedPage Today) -- Labels will still note serious neuropsychiatric risk but without the black box (Source: MedPage Today Public Health)
Source: MedPage Today Public Health - December 16, 2016 Category: American Health Source Type: news

FDA drops black box warning on Pfizer's anti-smoking drug
(Reuters) - U.S. health regulators on Friday allowed Pfizer Inc to remove a serious warning from the label of its smoking cessation treatment, Chantix, giving a new lease of life to the controversial drug that was approved a decade ago. (Source: Reuters: Health)
Source: Reuters: Health - December 16, 2016 Category: Consumer Health News Tags: healthNews Source Type: news

FDA Drug Safety Communication: FDA updates label for stop smoking drug Chantix (varenicline) to include potential alcohol interaction, rare risk of seizures, and studies of side effects on mood, behavior, or thinking
[03-09-2015] The U.S. Food and Drug Administration (FDA) is warning that the prescription smoking cessation medicine Chantix (varenicline) can change the way people react to alcohol. (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - December 15, 2016 Category: Drugs & Pharmacology Source Type: news

How to Quit Smoking
By Stacy Simon Tobacco use remains the single largest preventable cause of disease and premature death in the United States. Since the release of the Surgeon General’s Report on Smoking and Health 50 years ago, there have been 20 million deaths due to tobacco. Almost half the deaths from 12 different types of cancer combined – including lung, voice box, throat, esophagus, and bladder cancers – are attributable to cigarette smoking alone. In addition to cancer, smoking greatly increases the risk of debilitating long-term lung diseases like emphysema and chronic bronchitis. It also raises the risk for heart...
Source: American Cancer Society :: News and Features - November 16, 2016 Category: Cancer & Oncology Tags: Smoking/Tobacco Source Type: news

Varenicline and risk of self-harm: a nested case-control study - Tadrous M, Martins D, Yao Z, Mamdani MM, Juurlink DN, Gomes T, Antoniou T.
BACKGROUND: Smoking remains a serious public health concern. Pharmacotherapy for smoking cessation, including bupropion and varenicline, are proven means to increase quit rates. Post-marketing reports describing suicidal behaviours have raised concerns abo... (Source: SafetyLit)
Source: SafetyLit - November 8, 2016 Category: Global & Universal Tags: Alcohol and Other Drugs Source Type: news

Assessment of the risk of suicide-related events induced by concomitant use of antidepressants in cases of smoking cessation treatment with varenicline and assessment of latent risk by the use of varenicline - Akimoto H, Oshima S, Negishi A, Ohara K, Ohshima S, Inoue N, Kobayashi D.
Smoking Cessation Treatment (SCT) is a policy that has to be promoted for health economics, and expectations for the success of treatments with varenicline (VAR) are large. However, the Food and Drug Administration (FDA) have issued a warning on VAR-induce... (Source: SafetyLit)
Source: SafetyLit - September 25, 2016 Category: Global & Universal Tags: Alcohol and Other Drugs Source Type: news

By failing to update their warnings, drug regulators are letting patients down
Varenicline could help smokers quit, but misleading warnings might stop people trying it. Should regulators like the FDA be better at communicating research?US drug regulator the Food and Drug Administration (FDA) has issued warnings about possible side effects of taking varenicline. Varenicline (marketed as Chantix in the US, and Champix in the UK) is a drug whichcan help people stop smoking. The FDA ’s warnings are out of date, do not reflect the scientific evidence, and urgently need to be updated. They may have led the public and clinicians to incorrectly believe that there was strong scientific evidence that var...
Source: Guardian Unlimited Science - September 21, 2016 Category: Science Authors: Neil Davies and Kyla Thomas Tags: Smoking Science Society Health Drugs Source Type: news

FDA Advisers Recommend Removing Chantix Boxed Warning, but Vote Was Mixed (FREE)
By Amy Orciari Herman Edited by William E. Chavey, MD, MS An FDA advisory panel voted 10-9 on Wednesday to remove the black-box warning from the label of the smoking-cessation drug varenicline (Chantix), Reuters reports. The warning alerts prescribers … (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - September 15, 2016 Category: Primary Care Source Type: news

FDA panel votes to remove serious warning from Chantix label
Stephen FellerWASHINGTON, Sept. 15 (UPI) -- An advisory panel at the FDA voted to recommend the removal of a black box warning for psychological side effects of the drug smoking cessation drug Chantix. (Source: Health News - UPI.com)
Source: Health News - UPI.com - September 15, 2016 Category: Consumer Health News Source Type: news

FDA Panel Splits on Softening Chantix Warning
(MedPage Today) -- Panels split on removal of black box (Source: MedPage Today Public Health)
Source: MedPage Today Public Health - September 15, 2016 Category: American Health Source Type: news

Chantix Squeaks by With Favorable FDA Safety Vote
(MedPage Today) -- Panels split on removal of black box (Source: MedPage Today Primary Care)
Source: MedPage Today Primary Care - September 15, 2016 Category: Primary Care Source Type: news

Pfizer Moves Closer to FDA Removal of Suicide Warning on Chantix
Pfizer Inc. said two federal advisory panels have recommended removing the most serious warnings on its Chantix smoking cessation pill, clearing a major hurdle in the pharmaceutical giant ’s push to lessen concerns about using the medicine. (Source: WSJ.com: Health)
Source: WSJ.com: Health - September 14, 2016 Category: Pharmaceuticals Tags: PAID Source Type: news